本文關(guān)鍵詞：肝細(xì)胞癌手術(shù)方法及特殊類型肝癌的預(yù)后研究　出處：《北京協(xié)和醫(yī)學(xué)院》2017年博士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 多原發(fā)癌 肝細(xì)胞癌 預(yù)后 透明細(xì)胞癌 肝切除術(shù) 預(yù)后 復(fù)發(fā) 危險(xiǎn)因素 肝切除術(shù) 入肝血流阻塞 肝細(xì)胞癌 肝細(xì)胞癌 肝切除術(shù) 臨床分期

【摘要】：第一部分肝細(xì)胞癌合并多原發(fā)癌預(yù)后分析一26年隨訪研究研究目的多原發(fā)惡性腫瘤(MPM)是同一個(gè)體內(nèi)、不同器官中,同時(shí)或先后發(fā)生的兩種或多種原發(fā)性惡性腫瘤。目前,對(duì)合并存在肝細(xì)胞癌(HCC)的MPM患者相關(guān)研究報(bào)道罕見(jiàn)。我們對(duì)此類患者進(jìn)行了長(zhǎng)達(dá)26年的隨訪,以研究其臨床病理特征及預(yù)后。研究方法回顧性分析1989年至2010年于北京協(xié)和醫(yī)院外科確診的40例合并HCC的MPM患者,統(tǒng)計(jì)并分析其臨床病理特征和術(shù)后生存期。對(duì)照組為同期于我院確診并接受手術(shù)治療的448例僅罹患HCC患者。結(jié) 果在40例MPM患者中,11例為同時(shí)性MPM,29例為異時(shí)性MPM。合并HCC的常見(jiàn)肝外惡性腫瘤為肺癌(15%)、結(jié)直腸癌(12.5%)和甲狀腺癌(12.5%)。與僅罹患HCC的患者相比,合并存在HCC的MPM患者乙型病毒性肝炎感染率和甲胎蛋白(AFP)水平顯著較低(P=0.013,P=0.001)。MPM患者術(shù)后1年、3年和5年總體生存率分別為82.5%、64.5%和38.6%,與僅罹患HCC者相比無(wú)顯著差異(84.7%、54.2%和38.3%,P=0.726)。隨訪期間,24例MPM患者死亡,其中17例(70.8%)死因與HCC相關(guān)。單因素分析提示,MPM的同時(shí)性診斷、較高的Y谷氨酰轉(zhuǎn)移酶和/或AFP水平、HCC直徑大于5cm和血管侵犯顯著影響患者術(shù)后總體生存期。多因素分析提示,僅HCC直徑是影響MPM患者預(yù)后的獨(dú)立因素。結(jié) 論具有肝外惡性腫瘤的患者仍存在罹患HCC可能。多數(shù)合并HCC的MPM患者死因與HCC密切相關(guān);而經(jīng)過(guò)手術(shù)治療,患者可獲得與僅罹患HCC者無(wú)顯著差異的術(shù)后生存期。腫瘤直徑,而非肝外原發(fā)惡性腫瘤,是影響此類患者術(shù)后生存的獨(dú)立因素。第二部分Edmondson分級(jí)預(yù)測(cè)原發(fā)透明細(xì)胞型肝癌患者術(shù)后生存期研究目的透明細(xì)胞型肝癌是肝細(xì)胞癌罕見(jiàn)的亞型。我們對(duì)接受根治性肝切除術(shù)的透明細(xì)胞型肝癌患者進(jìn)行長(zhǎng)期隨訪并回顧性分析,研究影響透明細(xì)胞型肝癌患者術(shù)后腫瘤肝內(nèi)復(fù)發(fā)及預(yù)后的相關(guān)因素。研究方法回顧性分析1989年1月至2010年9月于北京協(xié)和醫(yī)院確診的38例透明細(xì)胞型肝癌患者的臨床資料及術(shù)后生存情況,2015年1月隨訪截止。同期,400例接受根治性肝切除術(shù)的普通肝細(xì)胞癌患者的臨床資料為對(duì)照。結(jié) 果透明細(xì)胞型肝癌患者的平均腫瘤直徑小于普通肝細(xì)胞癌(P0.001),腫瘤血管侵犯的發(fā)生率顯著低于普通肝細(xì)胞癌(P=0.029)。透明細(xì)胞型肝癌患者術(shù)后1年、3年和5年總體生存率分別為94.6%、67.3%和58.5%,1年、3年和5年無(wú)瘤生存率分別為89.2%、54.1%和48.6%,均顯著高于普通肝細(xì)胞癌患者(P=0.039,P=0.044)。多因素分析結(jié)果提示,與普通肝細(xì)胞癌不同,Edmondson分級(jí)是唯一影響透明細(xì)胞型肝癌患者術(shù)后腫瘤復(fù)發(fā)和生存期的獨(dú)立因素。結(jié) 論與普通肝細(xì)胞癌相比,透明細(xì)胞型肝癌惡性程度較低;透明細(xì)胞型肝癌患者術(shù)后腫瘤復(fù)發(fā)時(shí)間可能更長(zhǎng),預(yù)后可能較好。Edmondson分級(jí)是影響透明細(xì)胞型肝癌患者術(shù)后生存期的獨(dú)立因素;Edmondson分級(jí)較高的透明細(xì)胞型肝癌患者,術(shù)后可能需要更嚴(yán)密的隨訪和更積極的輔助治療。第三部分連續(xù)性Pringle手法對(duì)肝細(xì)胞癌患者預(yù)后的影響研究目的探討肝切除術(shù)中應(yīng)用連續(xù)性Pringle手法阻斷入肝血流對(duì)肝細(xì)胞癌患者預(yù)后的影響。研究方法回顧性分析1989年1月至2011年1月586例于北京協(xié)和醫(yī)院外科行根治性肝切除術(shù)的肝細(xì)胞癌患者的臨床資料及術(shù)后生存情況。290例術(shù)中應(yīng)用連續(xù)性Pringle手法(PM組),包括163例入肝血流阻斷時(shí)間小于15分鐘(PM-1組)和127例阻斷時(shí)間為15至30分鐘(PM-2組)。此外,296例術(shù)中未進(jìn)行入肝血流阻斷(OF組)。結(jié) 果PM組患者肝切除術(shù)中失血量顯著小于OF組(P=0.005);兩組患者圍手術(shù)期并發(fā)癥發(fā)生率無(wú)顯著差異。PM和OF組、PM-1和PM-2組患者術(shù)后總體生存期及無(wú)瘤生存期均無(wú)顯著差異(PM vs.OF,P=0.117,P=0.291;PM-1 vs.PM-2,P=0.344,P=0.103)。肝切除術(shù)中入肝血流阻斷與阻斷時(shí)間均不是影響肝細(xì)胞癌患者術(shù)后總體生存期或無(wú)瘤生存期的獨(dú)立危險(xiǎn)因素。結(jié) 論連續(xù)性Pringle手法可有效降低術(shù)中出血量,對(duì)肝細(xì)胞癌患者預(yù)后未產(chǎn)生不利影響。即使手術(shù)較為復(fù)雜,需要適當(dāng)延長(zhǎng)阻斷時(shí)間,Pringle手法仍然是肝切除術(shù)中進(jìn)行入肝血流阻斷安全、有效的方式。第四部分超巴塞羅那臨床分期標(biāo)準(zhǔn)肝細(xì)胞癌術(shù)后早期和晚期腫瘤復(fù)發(fā)治療策略研究背景肝切除術(shù)可延長(zhǎng)巴塞羅那臨床肝癌分期(BCLC)B期或C期肝細(xì)胞癌(HCC)患者的總體生存期(OS)。本文旨在探討影響B(tài)CLC B期或C期HCC患者術(shù)后腫瘤肝內(nèi)復(fù)發(fā)、復(fù)發(fā)腫瘤的治療方式及預(yù)后的相關(guān)因素。研究方法回顧性分析1989年1月至2011年10月397例接受根治性肝切除術(shù)的BCLC B期或C期患者的臨床病理特征及術(shù)后生存期。術(shù)后腫瘤肝內(nèi)復(fù)發(fā)分為早期復(fù)發(fā)(腫瘤復(fù)發(fā)時(shí)間1年)和晚期復(fù)發(fā)(復(fù)發(fā)時(shí)間≥1年)。結(jié) 果BCLC B期或C期HCC患者術(shù)后1年、3年和5年總體生存率分別為83.5%、50.1%和28.2%。73例患者確診腫瘤早期肝內(nèi)復(fù)發(fā);104例晚期復(fù)發(fā)。單因素變量分析提示,無(wú)腫瘤復(fù)發(fā)的患者OS顯著優(yōu)于復(fù)發(fā)者(P0.001),晚期復(fù)發(fā)患者術(shù)后OS顯著優(yōu)于早期復(fù)發(fā)者(P0.001);多因素變量分析提示,腫瘤直徑、腫瘤數(shù)目、血管侵犯是影響腫瘤肝內(nèi)復(fù)發(fā)的危險(xiǎn)因素。晚期復(fù)發(fā)患者接受根治性治療可獲得與未復(fù)發(fā)者無(wú)顯著性差異的OS(P=0.311)。結(jié) 論腫瘤復(fù)發(fā)時(shí)間和對(duì)復(fù)發(fā)腫瘤進(jìn)行根治性治療是BCLC B期或C期HCC患者預(yù)后的影響因素。對(duì)腫瘤晚期復(fù)發(fā)患者,根治性治療可能延長(zhǎng)其總生存期。
[Abstract]:The first part of hepatocellular carcinoma with multiple primary carcinoma prognosis analysis of a 26 year follow-up study to study multiple primary malignant tumors (MPM) are the same in different organs, simultaneously or successively occurred in two or more primary malignant tumor. At present, with the presence of hepatocellular carcinoma (HCC). MPM patients reported rare. We were followed for 26 years for such patients, in order to study the clinical pathological characteristics and prognosis. Methods a retrospective analysis from 1989 to 2010 in Peking Union Medical College Hospital surgery 40 patients diagnosed with HCC in patients with MPM, statistics and survival analysis of the clinicopathological characteristics and postoperative period in control group. For the same period in our hospital were diagnosed and 448 patients undergoing surgical treatment only in patients with HCC. Results in 40 cases of MPM patients, 11 cases of MPM, 29 cases of common liver for metachronous MPM. with HCC malignant tumors were lung cancer (15%), colorectal Cancer (12.5%) and thyroid carcinoma (12.5%). Compared with HCC patients, with the presence of hepatitis B virus infection rate and alpha fetoprotein MPM in patients with hepatitis HCC protein (AFP) levels were significantly lower (P=0.013, P=0.001).MPM patients after 1 years, 3 years and 5 years overall survival rate respectively. 82.5%, 64.5% and 38.6%, compared with HCC had no significant difference (84.7%, 54.2% and 38.3%, P=0.726). During the follow-up period, 24 cases of death in patients with MPM, including 17 cases (70.8%) of death associated with HCC. Single factor analysis showed that the MPM at the same time of diagnosis, Y glutamyl transferase higher the level of HCC and / or AFP, larger than 5cm in diameter and vascular invasion significantly affect postoperative overall survival. Multivariate analysis showed that only the diameter of HCC is an independent prognostic factor for MPM patients. Conclusion with extrahepatic malignant tumor patients are still suffering from HCC. MPM and HCC may be the cause of death in patients with HCC is closely related with the majority and; After surgery, there was no significant difference between the survival of patients with HCC and can be obtained only after the operation. The diameter of the tumor, and non extrahepatic primary malignant tumors, are independent factors affecting the survival of these patients after operation. The second part of the Edmondson classification of primary clear cell carcinoma of liver in patients with clear cell survival after study liver cancer is a subtype of hepatocellular carcinoma is rare. The clear cell type in patients with hepatocellular carcinoma undergoing radical hepatic resection for long-term follow-up and retrospective analysis, study on the effect of clear cell type of postoperative recurrence and prognosis of intrahepatic tumor related factors. Methods analysis of the clinical data from January 1989 to September 2010 in Peking Union Medical College Hospital diagnosed 38 cases of clear cell hepatocellular carcinoma patients and the postoperative survival situation review, January 2015. The end of the follow-up period, 400 patients received ordinary liver cells radical hepatic resection The clinical data of cancer patients as controls. Results the average tumor diameter of clear cell type in patients with HCC less than ordinary hepatocellular carcinoma (P0.001), the incidence of vascular invasion was significantly lower than that in normal liver cell carcinoma (P=0.029). 1 years after surgery in patients with hepatocellular carcinoma and clear cell type, 3 years and 5 years overall survival rate respectively. 94.6%, 67.3% and 58.5%, 1 years, 3 years and 5 years disease-free survival rates were 89.2%, 54.1% and 48.6%, were significantly higher than in patients with normal liver cell carcinoma (P=0.039, P=0.044). The results of multivariate analysis suggested that, unlike ordinary hepatocellular carcinoma, Edmondson classification is the only effect of clear cell type patients hepatocellular carcinoma after tumor recurrence and survival independent factors. Conclusion compared with normal liver cell carcinoma, clear cell carcinoma of liver malignancy is low; clear cell type of postoperative recurrence time may be longer, better prognosis may be.Edmondson grade is transparent Independent factors for survival in patients with hepatocellular carcinoma cells; clear cell hepatocellular carcinoma patients with high Edmondson grade, postoperative may need closer follow-up and more aggressive treatment. Objective: To explore the effect of the third part continuous Pringle technique on the prognosis of patients with hepatocellular carcinoma by hepatic blood inflow on the prognosis of patients with liver cells the application of continuous Pringle technique of cancer liver resection. Methods Retrospective analysis of the clinical data of 586 cases from January 1989 to January 2011 in Peking Union Medical College Hospital underwent radical hepatectomy for patients with hepatocellular carcinoma and postoperative survival using continuous Pringle technique of.290 patients (PM group), including 163 cases of hepatic blood flow the blocking time is less than 15 minutes (PM-1 group) and 127 cases of blocking time is 15 to 30 minutes (group PM-2). In addition, 296 patients without hepatic blood inflow occlusion (group OF). The patients in the PM group The blood loss in hepatectomy was significantly lower than group OF (P=0.005); the two groups of patients the incidence of perioperative complications had no significant difference between.PM and OF group, PM-1 and PM-2 groups of patients with postoperative overall survival and disease-free survival were not significantly different (PM vs.OF, P=0.117, P=0.291; PM-1 vs.PM-2, P =0.344. P=0.103). Liver resection for hepatic blood inflow occlusion and occlusion time were not affected in patients with hepatocellular carcinoma after overall survival or disease-free survival period independent risk factors. Conclusion continuous Pringle techniques can effectively reduce the amount of bleeding, on the prognosis of patients with hepatocellular carcinoma is not adversely affected even if the surgery is more complex. Need to extend the time, blocking, Pringle technique is still in hepatectomy for hepatic blood inflow occlusion is safe, effective way. The fourth part Barcelona clinical staging of hepatocellular carcinoma after treatment of early and late recurrence. The background liver resection can prolong the Barcelona Clinic Liver Cancer (BCLC) stage B or stage C hepatocellular carcinoma (HCC) patient overall survival (OS). This paper aims to explore the effects of BCLC B or C HCC in patients with postoperative tumor recurrence in the liver, the factors related to recurrence of cancer treatment and prognosis Methods Retrospective analysis from January 1989 to October 2011 397 patients underwent radical resection of the liver BCLC B or C patients with clinical pathological features and postoperative survival. Postoperative tumor recurrence was divided into early recurrence (recurrence time of 1 years) and late recurrence (recurrence time more than 1 years). BCLC B or C HCC patients after 1 years, 3 years and 5 years overall survival rates were 83.5%, 50.1% and 28.2%.73 of tumor patients were diagnosed early intrahepatic recurrence; 104 cases of late recurrence. Single factor analysis showed that patients with OS were significantly better than no recurrence of tumor recurrence (P0.001), late During the period of postoperative recurrence in patients with OS was significantly higher than that of early recurrence (P0.001); multivariate analysis showed that tumor size, tumor number, vascular invasion were risk factors of recurrence. The tumor in the liver of patients with late recurrence underwent radical treatment can be obtained without recurrence and no significant difference between OS (P=0.311). Conclusion the tumor time to recurrence and recurrence of tumor curative treatment is the prognostic factors of patients with BCLC B or C HCC. For patients with advanced cancer recurrence, radical therapy may prolong the overall survival.

【學(xué)位授予單位】：北京協(xié)和醫(yī)學(xué)院
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐衛(wèi)東,張春平,王桂榮;肝細(xì)胞癌的變化模式[J];國(guó)外醫(yī)學(xué)(內(nèi)科學(xué)分冊(cè));2000年10期

2 ;早期發(fā)現(xiàn)肝細(xì)胞癌可增加治療機(jī)會(huì)[J];河南醫(yī)學(xué)研究;2000年02期

3 Schafer DF,潘朝法,李蘇云;肝細(xì)胞癌[J];第四軍醫(yī)大學(xué)吉林軍醫(yī)學(xué)院學(xué)報(bào);2000年01期

4 中沼安二,林淑蘭,姚楨;有關(guān)小肝細(xì)胞癌病理學(xué)的最新認(rèn)識(shí)[J];日本醫(yī)學(xué)介紹;2000年05期

5 靜雨;;美國(guó)肝細(xì)胞癌發(fā)病率增高[J];國(guó)外醫(yī)學(xué)情報(bào);2000年01期

6 張玉勛;;肝細(xì)胞癌的非手術(shù)治療[J];國(guó)外醫(yī)學(xué)情報(bào);2000年05期

7 徐宏勇,李開宗,付由池,竇科峰,李景夢(mèng),何揚(yáng)舉;bcl-x,bax基因表達(dá)與肝細(xì)胞癌臨床病理特征的關(guān)系[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2001年14期

8 蔡端;多中心源肝細(xì)胞癌的特征:與肝內(nèi)轉(zhuǎn)移的比較[J];國(guó)外醫(yī)學(xué).外科學(xué)分冊(cè);2002年02期

9 張春平;與白介素-18水平升高有關(guān)的肝細(xì)胞癌自發(fā)性消退[J];國(guó)外醫(yī)學(xué)(內(nèi)科學(xué)分冊(cè));2003年03期

10 薛海鷗,岳莉;兒童肝細(xì)胞癌1例報(bào)告[J];錦州醫(yī)學(xué)院學(xué)報(bào);2003年04期

相關(guān)會(huì)議論文 前10條

1 卞讀軍;;肝細(xì)胞癌經(jīng)導(dǎo)管動(dòng)脈化療栓塞前后磁共振波譜研究[A];2009中華醫(yī)學(xué)會(huì)影像技術(shù)分會(huì)第十七次全國(guó)學(xué)術(shù)大會(huì)論文集[C];2009年

2 賈建偉;趙潔;;肝細(xì)胞癌領(lǐng)域研究現(xiàn)狀與進(jìn)展[A];中醫(yī)藥防治感染病之研究（九）——第九次全國(guó)中醫(yī)藥防治感染病學(xué)術(shù)交流大會(huì)論文集[C];2009年

3 陳孝平;;肝細(xì)胞癌外科治療進(jìn)展[A];湖北省第21屆腫瘤學(xué)術(shù)大會(huì)論文匯編[C];2011年

4 張杰;劉軍建;韓云;張寧;芮靜安;金城;周柔麗;;用熒光差異顯示法篩選肝細(xì)胞癌相關(guān)新基因[A];2000全國(guó)腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

5 馮仕庭;李子平;譚國(guó)勝;孫燦輝;彭振鵬;;中晚期肝細(xì)胞癌的多層螺旋CT血管造影表現(xiàn)及臨床應(yīng)用[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（下冊(cè)）[C];2006年

6 張法標(biāo);方哲平;王義;董輝;叢文銘;;上皮鈣粘素和β-連接素在兒童肝細(xì)胞癌中的表達(dá)及其臨床意義[A];2007年浙江省外科學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2007年

7 陳鐘杰;;螺旋CT診斷原發(fā)型肝細(xì)胞癌28例[A];2008年浙江省放射學(xué)年會(huì)論文匯編[C];2008年

8 賈克東;;肝細(xì)胞癌的診斷進(jìn)展及治療現(xiàn)狀[A];全國(guó)中西醫(yī)結(jié)合肝病新進(jìn)展講習(xí)班、江西省第二次中西醫(yī)結(jié)合肝病學(xué)術(shù)會(huì)議資料匯編[C];2010年

9 李秋萍;龍順欽;楊小兵;鄧宏;蔡姣芝;潘宗奇;河文峰;周宇姝;歐陽(yáng)育樹;廖桂雅;吳萬(wàn)垠;;癌服靈治療晚期肝細(xì)胞癌的臨床研究[A];2012·中國(guó)醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合醫(yī)師大會(huì)第三次會(huì)議論文集[C];2012年

10 朱明華;祝峙;劉曉紅;林靜;曲建慧;陳穎;曹曉哲;王力;倪燦榮;;乙型肝炎病毒感染與肝細(xì)胞癌發(fā)生關(guān)系的分子病理學(xué)研究[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2009年學(xué)術(shù)年會(huì)論文匯編[C];2009年

相關(guān)重要報(bào)紙文章 前10條

1 中國(guó)抗癌協(xié)會(huì)臨床腫瘤學(xué)協(xié)作專業(yè)委員會(huì)主任委員 秦叔逵;治療肝細(xì)胞癌 別只盯著靶向藥[N];健康報(bào);2013年

2 記者 王丹 管九蘋;肝細(xì)胞癌標(biāo)志物研究獲新進(jìn)展[N];健康報(bào);2013年

3 吳一福;四軍醫(yī)大唐都醫(yī)院發(fā)現(xiàn)硒蛋白P與肝細(xì)胞癌發(fā)生有關(guān)[N];中國(guó)醫(yī)藥報(bào);2007年

4 黎彬;肝癌研究重要進(jìn)展——預(yù)測(cè)肝癌轉(zhuǎn)移成為可能[N];中國(guó)醫(yī)藥報(bào);2004年

5 錢文彩;α2δ1陽(yáng)性細(xì)胞為新的肝細(xì)胞癌干細(xì)胞[N];中國(guó)醫(yī)藥報(bào);2013年

6 新美;基礎(chǔ)研究進(jìn)展推動(dòng)肝臟病學(xué)進(jìn)步[N];中國(guó)醫(yī)藥報(bào);2008年

7 周金蓮;MIB-1和bcl-2表達(dá)預(yù)測(cè)肝癌發(fā)生[N];中國(guó)醫(yī)藥報(bào);2004年

8 張金山;要靈活運(yùn)用影像學(xué)提供的方法和手段[N];中國(guó)高新技術(shù)產(chǎn)業(yè)導(dǎo)報(bào);2001年

9 李杰;不能手術(shù)切除肝細(xì)胞癌的治療[N];科技日?qǐng)?bào);2006年

10 ;修復(fù)肝細(xì)胞 改善肝功能[N];人民日?qǐng)?bào)海外版;2006年

相關(guān)博士學(xué)位論文 前10條

1 白蘭;乙肝病毒捕獲細(xì)胞因子和信號(hào)級(jí)聯(lián)以逃避宿主免疫并維持持續(xù)感染[D];武漢大學(xué);2014年

2 何洪衛(wèi);肝細(xì)胞癌內(nèi)γδT細(xì)胞浸潤(rùn)減少及功能缺陷的機(jī)制研究[D];復(fù)旦大學(xué);2014年

3 蔡曉燕;淋巴細(xì)胞在肝細(xì)胞癌和癌旁組織中的差異性表達(dá)研究[D];復(fù)旦大學(xué);2014年

4 向?qū)?細(xì)胞周期因子FoxM1促進(jìn)肝臟再殖的研究[D];第二軍醫(yī)大學(xué);2015年

5 康富標(biāo);共刺激分子B7-H3在肝細(xì)胞癌的表達(dá)及相關(guān)機(jī)制研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

6 楊純;Gankyrin正反饋調(diào)控Nrf2在肝細(xì)胞癌中發(fā)揮抗氧化作用[D];第二軍醫(yī)大學(xué);2015年

7 高霞;PNPLA3基因單核苷酸多態(tài)性及基因表達(dá)與乙肝病毒感染易感性及乙肝相關(guān)肝細(xì)胞癌的關(guān)聯(lián)性研究[D];河北醫(yī)科大學(xué);2016年

8 彭晨星;microRNA結(jié)合位點(diǎn)單核苷酸多態(tài)性對(duì)肝細(xì)胞癌預(yù)后影響的相關(guān)性研究[D];河北醫(yī)科大學(xué);2016年

9 田偉;γδT細(xì)胞免疫治療肝細(xì)胞癌的實(shí)驗(yàn)研究[D];山西醫(yī)科大學(xué);2016年

10 葉甲舟;RBM8A與肝細(xì)胞癌的相關(guān)性及對(duì)肝細(xì)胞癌增殖及凋亡生物學(xué)特性的影響[D];廣西醫(yī)科大學(xué);2016年

相關(guān)碩士學(xué)位論文 前10條

1 王飛;CDH17調(diào)控肝細(xì)胞癌的生物學(xué)機(jī)制的研究[D];福建醫(yī)科大學(xué);2015年

2 陳中博;咖啡攝入與肝細(xì)胞癌發(fā)病風(fēng)險(xiǎn)的Meta分析[D];河北醫(yī)科大學(xué);2015年

3 張華鵬;核受體輔激活蛋白5在肝細(xì)胞癌組織中的表達(dá)及其臨床意義[D];鄭州大學(xué);2015年

4 郭慧敏;血清sCD25測(cè)定在肝細(xì)胞癌診斷中的意義[D];鄭州大學(xué);2015年

5 凌青霞;雙氧化酶1（Duox1）在肝細(xì)胞癌中的表達(dá)調(diào)控及作用研究[D];復(fù)旦大學(xué);2014年

6 李會(huì)芬;血清Talin-1在肝細(xì)胞癌診斷中的作用[D];鄭州大學(xué);2015年

7 蒙錦瑩;血管生長(zhǎng)相關(guān)因子的血清濃度與肝細(xì)胞癌預(yù)后的相關(guān)性研究[D];蘭州大學(xué);2015年

8 戰(zhàn)勇;肝細(xì)胞癌術(shù)前造影參數(shù)與生物學(xué)表現(xiàn)相關(guān)性及術(shù)后復(fù)發(fā)相關(guān)因素討論[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

9 姚樂(lè);microRNA-32在肝細(xì)胞癌中的表達(dá)及其臨床預(yù)后意義[D];河北醫(yī)科大學(xué);2015年

10 吳華;MACC1在肝細(xì)胞癌中的表達(dá)與臨床意義[D];安徽醫(yī)科大學(xué);2015年

，

本文編號(hào)：1356531